

SARDA PROTEINS LTD.

Reg. Office: B-536-537, Matsya Industrial Area,  
Alwar- 301030 (Rajasthan)

Corporate office: Inside Data Ingenious Global Limited,  
Station Road, Durgapura, Jaipur-302018 (Rajasthan)

CIN: L15142RJ1991PLC006353

Phone: +91-7737822222

E Mail: sardaproteins@yahoo.com

Website: [www.sardaproteins.com](http://www.sardaproteins.com)

Date: 13.02.2020

To,  
BSE Limited,  
25<sup>th</sup> Floor, P.J. Towers,  
Dalal Street,  
Fort, Mumbai-400 001

(BY BSE LISTING CENTRE)

**Sub: Disclosures pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("Listing Regulations").**

**Ref.: Sarda Proteins Limited, Scrip Code: 519242, Security ID: SRDAPRT.**

Dear Sir /Ma'am,

In accordance with Regulations 33 of Listing Regulations, we are submitting herewith the Un-audited Financial Results of the company for the quarter/nine months ended on 31<sup>st</sup> December, 2019 and Limited review report on the Un-audited Financial Results of the company for the quarter/nine months ended on 31<sup>st</sup> December, 2019.

We request you to take the same on record.

Thanking You,  
Yours Faithfully


**FOR SARDA PROTEINS LTD.**

For SARDA PROTEINS LTD

  
Company Secretary

**AMIT KUMAR MODI  
COMPANY SECRETARY &  
COMPLIANCE OFFICER  
M.NO.: 29371**

Encl: a/a



*Khetawat Agarwal & Co.*  
*Chartered Accountants*

## Limited Review Report

### **Review Report to Sarda Proteins Limited, Alwar**


We have reviewed the accompanying statement of unaudited financial results of Sarda proteins limited, G-1-177 (A), MIA , ALWAR-301030 for the period ended 31<sup>st</sup> December, 2019 . This statement is the responsibility of the company's management and has been approved by the board of directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2400, *engagements to review financial statements* issued by the institute of chartered accountants of India. This standard requires that we plan and perform the review to obtain the moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquires of company personal and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable accounting standard and other recognized accounting practices and policies has not disclosed the information required to be disclose in terms of regulation 33 of the SEBI (listing obligations and disclosures requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khetawat Agarwal & Co  
Chartered Accountants

FRN NO. 003960C


  
M.L. AGARWAL

(Partner)

M. No. 072854

Place: Alwar

Dated: 13/02/2020



Office : 103, 1<sup>st</sup> Floor, City Centre, Ashok Circle, Alwar-301001 (Rajasthan)  
Phone : Office 0144 - 2340924, 7014347644  
Mobile : 9414215353 (ML Agarwal)  
E-mail : khetawatagarwal21@gmail.com

# SARDA PROTEINS LTD

Reg. Off: B-536-537, Mansya Industrial Area, Alwar-301030 (Rajasthan)  
 Phone: +91 7737822222, E-Mail: sardaproteins@yahoo.com, website: www.sardaproteins.com  
 CIN: L15142RJ1991PLC006853

## STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER 2019

		Rs. in Lakhs					
S. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	(Audited)
I	Revenue from Operations	141.86	171.81	202.85	351.42	502.05	714.51
II	Other Income	1.98	4.65	-	6.04	2.93	10.15
III	<b>Total Income (I+II)</b>	<b>143.84</b>	<b>176.46</b>	<b>202.85</b>	<b>357.46</b>	<b>504.98</b>	<b>724.66</b>
IV	Expenses:						
	Cost of Material Consumed						
	Purchase of Stock -in- Trade	130.30	170.75	199.85	338.30	453.92	659.65
	Changes in inventories of						
	Finished Goods						
	Work in Progress						
	Stock in Trade					42.82	42.82
	Employee Benefit Expenses	2.44	3.01	3.38	8.83	15.02	18.35
	Finance Cost		0.02	-	0.03	-	0.20
	Depreciation and Amortisation Expenses		0.06	0.23	0.25	0.67	0.90
	Other expenses	1.50	0.85	1.63	6.44	9.82	11.48
	<b>Total Expenses (IV)</b>	<b>134.24</b>	<b>174.69</b>	<b>205.09</b>	<b>353.85</b>	<b>522.25</b>	<b>733.40</b>
V	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	9.60	1.17	(2.24)	3.61	(17.27)	(8.74)
VI	Exceptional Items						
VII	Profit/(Loss) before Tax (V-VI)	9.60	1.17	(2.24)	3.61	(17.27)	(8.74)
VIII	Tax Expense						
	(1) Current Tax						
	(2) Deferred Tax					(3.00)	3.61
IX	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	9.60	1.17	(2.24)	3.61	(14.27)	(12.35)
X	Profit/(Loss) from Discontinued Operations						
XI	Tax Expenses of Discontinued Operations						
	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)						
XIII	Profit/(Loss) for the Period (IX+XII)	9.60	1.17	(2.24)	3.61	(14.27)	(12.35)
XIV	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss						
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss						
	B (i) Items will be reclassified to Profit or Loss						
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss						
XV	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other Comprehensive Income for the period)	9.60	1.17	(2.24)	3.61	(14.27)	(12.35)
XVI	Earnings per Equity Share						
	(1) Basic	0.56	0.07	(0.13)	0.21	(0.83)	(0.72)
	(2) Diluted	0.56	0.07	(0.13)	0.21	(0.83)	(0.72)
XVII	Paid Up Equity Share Capital, Equity Shares Of Face Value Rs. 10 each	172.59	172.59	172.59	172.59	172.59	172.59

**Notes:**

1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 13th February 2020.
2. Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
3. Segment Results as per AS is not applicable as dealing in only one segment i.e. "Agro Products".
4. No Investor Complaints were received during the quarter ended 31-Dec-2019 nor any pending as on 01-Jan-2020.

on behalf of the Board  
Sarda Proteins Ltd

**For SARDA PROTEINS LTD.**



Place: Jaipur  
Date: 13 Feb-2020

Deepak Datta (DIN: 01672415)  
Managing Director

Director